Lantern Historical Financial Ratios

LTRN Stock

USD 3.66 0.19 4.94%

Lantern Pharma is lately reporting on over 92 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Lantern Pharma financial condition quickly.

Quick Ratio Current Ratio

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

About Lantern Financial Ratios Analysis

Lantern PharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Lantern Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Lantern financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Lantern Pharma history.

Lantern Pharma Financial Ratios Chart

At this time, Lantern Pharma's PTB Ratio is very stable compared to the past year. As of the 26th of March 2025, PB Ratio is likely to grow to 1.07, while Book Value Per Share is likely to drop 2.50.

Average Payables Cash Per Share Pocfratio Income Quality Intangibles To Total Assets

Add Fundamental

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Income Quality

An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.

Intangibles To Total Assets

The ratio of a company's intangible assets (like goodwill and patents) to its total assets.

Most ratios from Lantern Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Lantern Pharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.At this time, Lantern Pharma's PTB Ratio is very stable compared to the past year. As of the 26th of March 2025, PB Ratio is likely to grow to 1.07, while Book Value Per Share is likely to drop 2.50.

	2022	2023	2024	2025 (projected)
Current Ratio	20.99	16.18	14.56	14.43
Net Debt To EBITDA	2.58	1.37	1.24	1.62

Current Ratio Net Debt To E B I T D A

Lantern Pharma fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield
Ptb Ratio		0.77	-0.69	-0.82	0.76	-0.5	1.0	-0.82	-1.0	0.62	-0.81	-0.61	0.8	0.77	0.92	0.38	0.65	0.92	0.67	0.77	-1.0	0.92	0.89	0.96	0.92	-0.68
Book Value Per Share	0.77		-0.66	-0.81	0.94	-0.55	0.77	-0.81	-0.76	0.58	-0.81	-0.54	0.88	1.0	0.9	0.26	0.72	0.9	0.15	0.68	-0.76	0.91	0.9	0.89	0.91	-0.66
Free Cash Flow Yield	-0.69	-0.66		0.95	-0.62	0.9	-0.69	0.95	0.69	-0.95	0.96	0.96	-0.92	-0.66	-0.86	-0.74	-0.93	-0.86	-0.04	-0.28	0.69	-0.85	-0.89	-0.78	-0.85	1.0
Operating Cash Flow Per Share	-0.82	-0.81	0.95		-0.77	0.77	-0.82	1.0	0.82	-0.88	1.0	0.89	-0.94	-0.81	-0.96	-0.65	-0.88	-0.96	-0.17	-0.48	0.82	-0.96	-0.97	-0.92	-0.96	0.95
Average Payables	0.76	0.94	-0.62	-0.77		-0.43	0.76	-0.78	-0.74	0.57	-0.77	-0.5	0.79	0.94	0.86	0.2	0.61	0.86	0.19	0.82	-0.74	0.87	0.86	0.87	0.87	-0.62
Capex To Depreciation	-0.5	-0.55	0.9	0.77	-0.43		-0.5	0.77	0.51	-0.83	0.79	0.84	-0.85	-0.55	-0.69	-0.62	-0.95	-0.69	0.12	-0.05	0.51	-0.67	-0.72	-0.58	-0.67	0.91
Pb Ratio	1.0	0.77	-0.69	-0.82	0.76	-0.5		-0.82	-1.0	0.62	-0.81	-0.61	0.8	0.77	0.92	0.38	0.65	0.92	0.67	0.77	-1.0	0.92	0.89	0.96	0.92	-0.68
Free Cash Flow Per Share	-0.82	-0.81	0.95	1.0	-0.78	0.77	-0.82		0.82	-0.88	1.0	0.89	-0.94	-0.81	-0.96	-0.65	-0.88	-0.96	-0.17	-0.48	0.82	-0.96	-0.97	-0.92	-0.96	0.95
Roic	-1.0	-0.76	0.69	0.82	-0.74	0.51	-1.0	0.82		-0.62	0.81	0.61	-0.79	-0.76	-0.92	-0.39	-0.65	-0.92	-0.68	-0.76	1.0	-0.92	-0.89	-0.95	-0.92	0.69
Inventory Turnover	0.62	0.58	-0.95	-0.88	0.57	-0.83	0.62	-0.88	-0.62		-0.89	-0.99	0.87	0.58	0.79	0.65	0.81	0.79	0.0	0.26	-0.62	0.78	0.81	0.7	0.77	-0.95
Net Income Per Share	-0.81	-0.81	0.96	1.0	-0.77	0.79	-0.81	1.0	0.81	-0.89		0.9	-0.95	-0.81	-0.96	-0.66	-0.9	-0.96	-0.15	-0.45	0.8	-0.95	-0.97	-0.91	-0.95	0.96
Days Of Inventory On Hand	-0.61	-0.54	0.96	0.89	-0.5	0.84	-0.61	0.89	0.61	-0.99	0.9		-0.85	-0.54	-0.78	-0.73	-0.83	-0.78	0.0	-0.19	0.61	-0.76	-0.8	-0.69	-0.76	0.96
Payables Turnover	0.8	0.88	-0.92	-0.94	0.79	-0.85	0.8	-0.94	-0.79	0.87	-0.95	-0.85		0.88	0.95	0.52	0.92	0.95	0.11	0.47	-0.79	0.94	0.96	0.89	0.94	-0.92
Cash Per Share	0.77	1.0	-0.66	-0.81	0.94	-0.55	0.77	-0.81	-0.76	0.58	-0.81	-0.54	0.88		0.9	0.26	0.72	0.9	0.14	0.67	-0.76	0.91	0.9	0.89	0.91	-0.66
Pocfratio	0.92	0.9	-0.86	-0.96	0.86	-0.69	0.92	-0.96	-0.92	0.79	-0.96	-0.78	0.95	0.9		0.5	0.83	1.0	0.34	0.66	-0.92	1.0	1.0	0.99	1.0	-0.86
Interest Coverage	0.38	0.26	-0.74	-0.65	0.2	-0.62	0.38	-0.65	-0.39	0.65	-0.66	-0.73	0.52	0.26	0.5		0.67	0.5	0.0	-0.08	-0.39	0.49	0.52	0.43	0.49	-0.74
Capex To Operating Cash Flow	0.65	0.72	-0.93	-0.88	0.61	-0.95	0.65	-0.88	-0.65	0.81	-0.9	-0.83	0.92	0.72	0.83	0.67		0.83	-0.03	0.22	-0.65	0.82	0.85	0.74	0.82	-0.94
Pfcf Ratio	0.92	0.9	-0.86	-0.96	0.86	-0.69	0.92	-0.96	-0.92	0.79	-0.96	-0.78	0.95	0.9	1.0	0.5	0.83		0.34	0.66	-0.92	1.0	1.0	0.99	1.0	-0.86
Days Payables Outstanding	0.67	0.15	-0.04	-0.17	0.19	0.12	0.67	-0.17	-0.68	0.0	-0.15	0.0	0.11	0.14	0.34	0.0	-0.03	0.34		0.63	-0.68	0.34	0.27	0.45	0.34	-0.03
Income Quality	0.77	0.68	-0.28	-0.48	0.82	-0.05	0.77	-0.48	-0.76	0.26	-0.45	-0.19	0.47	0.67	0.66	-0.08	0.22	0.66	0.63		-0.76	0.67	0.62	0.74	0.67	-0.27
Roe	-1.0	-0.76	0.69	0.82	-0.74	0.51	-1.0	0.82	1.0	-0.62	0.8	0.61	-0.79	-0.76	-0.92	-0.39	-0.65	-0.92	-0.68	-0.76		-0.92	-0.89	-0.95	-0.92	0.68
Ev To Operating Cash Flow	0.92	0.91	-0.85	-0.96	0.87	-0.67	0.92	-0.96	-0.92	0.78	-0.95	-0.76	0.94	0.91	1.0	0.49	0.82	1.0	0.34	0.67	-0.92		1.0	0.99	1.0	-0.85
Pe Ratio	0.89	0.9	-0.89	-0.97	0.86	-0.72	0.89	-0.97	-0.89	0.81	-0.97	-0.8	0.96	0.9	1.0	0.52	0.85	1.0	0.27	0.62	-0.89	1.0		0.97	1.0	-0.88
Return On Tangible Assets	0.96	0.89	-0.78	-0.92	0.87	-0.58	0.96	-0.92	-0.95	0.7	-0.91	-0.69	0.89	0.89	0.99	0.43	0.74	0.99	0.45	0.74	-0.95	0.99	0.97		0.99	-0.78
Ev To Free Cash Flow	0.92	0.91	-0.85	-0.96	0.87	-0.67	0.92	-0.96	-0.92	0.77	-0.95	-0.76	0.94	0.91	1.0	0.49	0.82	1.0	0.34	0.67	-0.92	1.0	1.0	0.99		-0.85
Earnings Yield	-0.68	-0.66	1.0	0.95	-0.62	0.91	-0.68	0.95	0.69	-0.95	0.96	0.96	-0.92	-0.66	-0.86	-0.74	-0.94	-0.86	-0.03	-0.27	0.68	-0.85	-0.88	-0.78	-0.85

Click cells to compare fundamentals

Lantern Pharma Account Relationship Matchups

Lantern Pharma fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	6.08	1.22	1.17	1.13	1.02	1.07
Book Value Per Share	3.17	6.56	5.16	3.77	3.4	2.5
Free Cash Flow Yield	(0.0473)	(0.12)	(0.2)	(0.31)	(0.36)	(0.34)
Operating Cash Flow Per Share	(0.91)	(0.97)	(1.18)	(1.32)	(1.52)	(1.6)
Capex To Depreciation	4.76	2.29	2.76	1.28	1.47	1.4
Pb Ratio	6.08	1.22	1.17	1.13	1.02	1.07
Free Cash Flow Per Share	(0.91)	(0.97)	(1.18)	(1.32)	(1.52)	(1.6)
Roic	(0.29)	(0.17)	(0.25)	(0.43)	(0.5)	(0.47)
Net Income Per Share	(0.95)	(1.13)	(1.3)	(1.47)	(1.69)	(1.78)
Payables Turnover	0.003402	0.007836	0.14	0.17	0.15	0.16
Cash Per Share	3.09	6.49	5.09	3.81	3.43	2.5
Pocfratio	(21.19)	(8.22)	(5.13)	(3.23)	(2.91)	(3.06)
Capex To Operating Cash Flow	(0.002855)	(0.001463)	(0.002181)	(0.001306)	(0.001175)	(0.001234)
Pfcf Ratio	(21.13)	(8.2)	(5.12)	(3.23)	(2.91)	(3.05)
Days Payables Outstanding	107.3K	46.6K	2.6K	2.2K	2.5K	2.4K
Income Quality	0.88	0.96	0.86	0.9	0.81	0.7
Roe	(0.3)	(0.17)	(0.25)	(0.39)	(0.45)	(0.43)
Ev To Operating Cash Flow	(17.81)	(3.37)	(2.22)	(1.72)	(1.55)	(1.63)
Pe Ratio	(20.27)	(7.08)	(4.65)	(2.91)	(2.62)	(2.75)
Return On Tangible Assets	(0.29)	(0.17)	(0.24)	(0.37)	(0.33)	(0.35)
Ev To Free Cash Flow	(17.76)	(3.37)	(2.22)	(1.72)	(1.55)	(1.62)
Earnings Yield	(0.0493)	(0.14)	(0.21)	(0.34)	(0.4)	(0.38)
Net Debt To E B I T D A	3.24	4.18	2.58	1.37	1.24	1.62
Current Ratio	36.64	31.26	20.99	16.18	14.56	14.43
Tangible Book Value Per Share	3.17	6.56	5.16	3.77	3.4	2.5
Shareholders Equity Per Share	3.17	6.56	5.16	3.77	3.4	2.5
Capex Per Share	0.002594	0.001421	0.002566	0.001728	0.001555	0.001475
Graham Net Net	2.98	6.26	4.8	3.56	3.2	2.36
Enterprise Value Over E B I T D A	(17.04)	(2.91)	(1.97)	(1.56)	(1.41)	(1.48)
Price Earnings Ratio	(20.27)	(7.08)	(4.65)	(2.91)	(2.62)	(2.75)
Price Book Value Ratio	6.08	1.22	1.17	1.13	1.02	1.07
Price Earnings To Growth Ratio	(0.14)	(0.37)	(0.31)	(0.22)	(0.2)	(0.21)
Days Of Payables Outstanding	107.3K	46.6K	2.6K	2.2K	2.5K	2.4K
Price To Operating Cash Flows Ratio	(21.19)	(8.22)	(5.13)	(3.23)	(2.91)	(3.06)
Price To Free Cash Flows Ratio	(21.13)	(8.2)	(5.12)	(3.23)	(2.91)	(3.05)

When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:

How To Invest In Lantern

Details

Is Lantern Stock a good investment?

Details

What is Lantern Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.78)

Return On Assets

(0.34)

Return On Equity

(0.53)

The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Lantern Historical Financial Ratios

About Lantern Financial Ratios Analysis

Lantern Pharma Financial Ratios Chart

Average Payables

Income Quality

Intangibles To Total Assets

Lantern Pharma fundamentals Correlations

Lantern Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lantern Pharma fundamentals Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Cash Per Share	+ 1.0	Book Value Per Share
Earnings Yield	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Free Cash Flow Per Share

Roe	- 1.0	Pb Ratio
Roic	- 1.0	Pb Ratio
Roe	- 1.0	Ptb Ratio
Roic	- 1.0	Ptb Ratio
Days Of Inventory On Hand	- 0.99	Inventory Turnover
Pe Ratio	- 0.97	Net Income Per Share